110099-99-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinecarbonyl chloride, 2-chloro(9CI) is used as a reactive intermediate for the production of pharmaceuticals. It plays a crucial role in the synthesis of pyrimidine derivatives, which are key components in the development of various drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Pyrimidinecarbonyl chloride, 2-chloro(9CI) is employed as a building block for the synthesis of agrochemicals. Its reactivity and ability to form heterocyclic compounds make it a valuable component in the development of effective agricultural products.
Used in Organic Synthesis:
5-Pyrimidinecarbonyl chloride, 2-chloro(9CI) is used as an acylating agent in organic synthesis. Its high reactivity allows for the formation of various chemical compounds, contributing to the production of a wide range of fine chemicals.
Safety Precautions:
Due to its corrosive nature, 5-Pyrimidinecarbonyl chloride, 2-chloro(9CI) can cause irritation to the skin, eyes, and respiratory system. It is essential to handle 5-Pyrimidinecarbonyl chloride, 2-chloro- (9CI) with caution and use appropriate protective equipment. Additionally, it should be stored and handled in a well-ventilated area to minimize the risk of exposure.

Upstream product

• 38324-83-3 2-oxo-1,2-dihydropyrimidine-5-carboxylic acid 
• 38324-83-3 2-hydroxypyrimidine-5-carboxylic acid 
• 374068-01-6 2-bromopyrimidine-5-carboxylic acid 
• 95928-49-7 ethyl 2-oxo-1,2-dihydropyrimidine-5-carboxylate 
• 33458-27-4 ethyl 2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 89793-12-4 ethyl 2-chloropyrimidine-5-carboxylate 
• 73781-88-1 ethyl 2-(methylthio)pyrimidine-5-carboxylate 

Downstream Products

• 110100-00-0 1-(2-chloropyrimidin-5-yl)ethan-1-one 
• 110100-09-9 2-(2-chloropyrimidin-5-yl)propan-2-ol 
• 110100-02-2 (2-chloropyrimidin-5-yl)(phenyl)methanone 
• 110100-07-7 1-benzyl-5-pentanoyl-2(1H)-pyrimidinone 
• 1753-50-0 2-chloropyrimidine-5-carbonitrile 
• 1213234-72-0 (5-{2-[1-(3,4,5-Trichlorobenzyl)-1H-1,2,3-triazol-4-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid 
• 856595-94-3 2-chloropyrimindine-5-carboxaminde 
• 1213234-96-8 5-(2H-tetrazol-5-yl)-2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]pyrimidine 
• 1213234-97-9 ethyl (5-{2-[1-(3,4,5-trichlorobenzyl)-1H-1,2,3-triazol-4-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetate 
• 1360598-99-7 2-chloro-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)-amide 
• 1648843-04-2 {2-[({5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl}sulfanyl)methyl]-4-(trifluoromethoxy)phenyl}boronic acid 
• 1240496-04-1 2-mercapto-pyrimidine-5-carboxylic acid (4-fluoro-phenyl)-amide 
• 1360443-21-5 2-chloro-N-methylpyrimidine-5-carboxamide 

Relevant academic research and scientific papers

6-5 FUSED RINGS AS C5a INHIBITORS

The present disclosure provides, inter alia, Compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Effective combinatorial immunotherapy for castration-resistant prostate cancer

A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade using a

2- [5- [N- (4 -FLUOROPHENYL) CARBAMOYL] PYRIMIDIN- 2 - YLSULFANYLMETHYL] -4- (TRIFLUOROMET HOXY) PHENYL] BORONIC ACID

There is disclosed a pyrimidinecarboxamide compound useful as a pharmaceutical agent, synthetic processes, and pharmaceutical compositions which include the pyrimidinecarboxamide compound. More specifically, there is disclosed a CXCRl/2 inhibitor useful f

HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and tr

Organic compounds

The present invention relates to novel benzimidazole derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them, wherein the compounds have the formula (I): in which the substitutents are as defined in claim 1 and salts, solvates, hydrates and N-oxides thereof.

Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide].

We investigated the structure-activity relationship studies of N-[3, 5-bis(trifluoromethyl)phenyl][2-chloro-4-(trifluoromethyl)pyrimidin-5 -yl]carboxamide (1), an inhibitor of transcription mediated by both NF-kappaB and AP-1 transcription factors, with the goal of improving its potential oral bioavailability. Compounds were examined for cell-based activity, were fit to Lipinski's rule of 5, and were examined for potential gastrointestinal permeability using the intestinal epithelial cell line, Caco-2. Selected groups were substituted at the 2-, 4-, and 5-positions of the pyrimidine ring using solution-phase combinatorial methodology. The introduction of a fluorine in the place of 2-chlorine of 1 resulted in a compound with comparable activity. However, other substitutions at the 2-position resulted in a loss of activity. The trifluoromethyl group at the 4-position could be replaced with a methyl, ethyl, chlorine, or phenyl without a substantial loss of activity. The carboxamide group at the 5-position is critical for activity. If it was moved to the 6-position, the activity was lost. The 2-methyl analogue of 1 (81) showed comparable in vitro activity and improved Caco-2 permeability compared to 1.

Organomanganese(II) Reagents in the Synthesis of 5-Pyrimidinyl Ketones

Substituted alkyl 5-pyrimidinyl ketones were formed from acid chlorides of pyrimidine-5-carboxylic acids and alkylmanganese(II) iodides.The corresponding alcohols were also formed in the case of sterically less requiring organomanganese reagents and the a